Search research articles
Contact Us
Filters
Showing results (61-70 of 92) with videos related to
Page
of 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 29, 2006
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR
J Pfisterer, A du Bois, J Sehouli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 16, 2004
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study
G von Minckwitz, J-U Blohmer, G Raab, et al.
Gynecologic Oncology
|
January 22, 2005
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)
A du Bois, A Belau, U Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2001
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study
G von Minckwitz, S D Costa, G Raab, et al.
Human Mutation
|
March 25, 1999
Peutz-Jeghers syndrome: four novel inactivating germline mutations in the STK11 gene. Mutations in brief no. 227. Online
R Kruse, S Uhlhaas, C Lamberti, et al.
Oncology
|
April 6, 2005
High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer
J Stemmler, W Mair, M Stauch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 9, 2012
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
W Eiermann, M Rezai, S Kümmel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 26, 2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
V Möbus, C Jackisch, H J Lück, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2007
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
G von Minckwitz, S Kümmel, A du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 5, 2008
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
O Gluz, U A Nitz, N Harbeck, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 92) with videos related to
Sort By:
Page
of 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 29, 2006
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR
J Pfisterer, A du Bois, J Sehouli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 16, 2004
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study
G von Minckwitz, J-U Blohmer, G Raab, et al.
Gynecologic Oncology
|
January 22, 2005
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)
A du Bois, A Belau, U Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2001
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study
G von Minckwitz, S D Costa, G Raab, et al.
Human Mutation
|
March 25, 1999
Peutz-Jeghers syndrome: four novel inactivating germline mutations in the STK11 gene. Mutations in brief no. 227. Online
R Kruse, S Uhlhaas, C Lamberti, et al.
Oncology
|
April 6, 2005
High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer
J Stemmler, W Mair, M Stauch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 9, 2012
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
W Eiermann, M Rezai, S Kümmel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 26, 2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
V Möbus, C Jackisch, H J Lück, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2007
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
G von Minckwitz, S Kümmel, A du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 5, 2008
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
O Gluz, U A Nitz, N Harbeck, et al.
Page
of 10